TECH vs. BRKR, A, CRL, DHR, IQV, MTD, RVTY, TMO, WAT, and ILMN
Should you be buying Bio-Techne stock or one of its competitors? The main competitors of Bio-Techne include Bruker (BRKR), Agilent Technologies (A), Charles River Laboratories International (CRL), Danaher (DHR), IQVIA (IQV), Mettler-Toledo International (MTD), Revvity (RVTY), Thermo Fisher Scientific (TMO), Waters (WAT), and Illumina (ILMN).
Bio-Techne vs. Its Competitors
Bio-Techne (NASDAQ:TECH) and Bruker (NASDAQ:BRKR) are both mid-cap life sciences tools & services companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.
98.9% of Bio-Techne shares are owned by institutional investors. Comparatively, 79.5% of Bruker shares are owned by institutional investors. 3.9% of Bio-Techne shares are owned by insiders. Comparatively, 27.3% of Bruker shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Bio-Techne has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Comparatively, Bruker has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500.
Bio-Techne has a net margin of 10.89% compared to Bruker's net margin of 2.31%. Bruker's return on equity of 19.47% beat Bio-Techne's return on equity.
In the previous week, Bruker had 4 more articles in the media than Bio-Techne. MarketBeat recorded 11 mentions for Bruker and 7 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 1.35 beat Bruker's score of 1.25 indicating that Bio-Techne is being referred to more favorably in the media.
Bio-Techne presently has a consensus price target of $72.00, indicating a potential upside of 35.50%. Bruker has a consensus price target of $52.89, indicating a potential upside of 24.68%. Given Bio-Techne's stronger consensus rating and higher probable upside, research analysts clearly believe Bio-Techne is more favorable than Bruker.
Bio-Techne pays an annual dividend of $0.32 per share and has a dividend yield of 0.6%. Bruker pays an annual dividend of $0.20 per share and has a dividend yield of 0.5%. Bio-Techne pays out 39.0% of its earnings in the form of a dividend. Bruker pays out 38.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
Bio-Techne has higher earnings, but lower revenue than Bruker. Bio-Techne is trading at a lower price-to-earnings ratio than Bruker, indicating that it is currently the more affordable of the two stocks.
Summary
Bio-Techne beats Bruker on 12 of the 18 factors compared between the two stocks.
Get Bio-Techne News Delivered to You Automatically
Sign up to receive the latest news and ratings for TECH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TECH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Bio-Techne Competitors List
Related Companies and Tools
This page (NASDAQ:TECH) was last updated on 7/5/2025 by MarketBeat.com Staff